Usually, when we’re scanning the daily email from the Federal Circuit for takings decisions of interest, we look for “United States” as the defendant, and our eyes glaze over the other cases on the court’s docket such as patent matters. But today, we were rewarded: a takings issue in a patent matter.
In Celgene Corp. v. Peter, No. 18-1167 (July 30, 2019), the court concluded that the invalidation of an issued patent via inter partes review was not a taking. This issue was ripened by the U.S. Supreme Court’s recent decision in Oil States, which noted that patents may be “property for purposes of the Due Process Clause or the Takings Clause.”
Celgene obtained patents for “a system to safely distribute thalidomide to patients.” Slip op. at 4. The Coalition for Affordable Drugs objected, and sought inter partes review, which according to the USPTO is, “a trial proceeding
Continue Reading Fed Cir: Inter Partes Reexamination Of Patents Isn’t A Taking

